Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, ...
Investor's Business Daily on MSN
Sanofi edges higher as immunology powerhouse, Dupixent, wallops forecasts
Sanofi stock edged higher Thursday after its immunological powerhouse, Dupixent, handily beat Wall Street's fourth-quarter ...
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
LONDON, Jan 29 (Reuters) - French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug ...
The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.
Zacks.com on MSN
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2025 adjusted earnings per share (EPS) of $11.44, which ...
The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results